COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT

Retina

Volumn 40, Issue 6, 2020, Pages 1044-1052

  Ozsaygili, Cemal ^a   Duru, Necati ^a  

^a Kayseri Municipality   (Turkey)

Author keywords

Aflibercept; Dexamethasone implant; Serous retinal detachment; Treatment naive diabetic macular edema

Indexed keywords

AFLIBERCEPT; DEXAMETHASONE; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; GLUCOCORTICOID; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SINGLE BLIND PROCEDURE; COMPLICATION; DIABETIC RETINOPATHY; DRUG IMPLANT; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RETINA; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL DETACHMENT; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85085230698     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000002537     Document Type: Article

References (46)

1. Whiting D, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–321.
2. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137–149.
3. Yau JW, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–564.
4. Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552–563.
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103:1796–1806.
6. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2011;118:1819–1826.
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The restore Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–625.
8. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II Study. Diabetes Care 2010;33:2399–2405.
9. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology 2010;117:1078–1086.
10. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904–1914.
11. Paper O, Guigou S, Pommier S, et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica 2015;233:169–175.
12. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223–232.
13. Rechtman E, Harris A, Garzozi HJ, Ciulla TA. Pharmacologic therapies for diabetic retinopathy and diabetic macular edema. Clin Ophthalmol 2007;1:383–391.
14. Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275–1293.
15. Richter B, Kohner E. Medical interventions for diabetic retinopathy. In: Wardnold R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London, United Kingdom: BMJ Books; 2004:331–340.
16. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414–1431.
17. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. Diabetes Care 2003;26:2653–2664.
18. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010;30:1412–1419.
19. Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 2009;116:80–86.
20. Ozdemir H, Karacorlu M, Karacorlu S. Serous macular detachment in diabetic cystoid macular edema. Acta Ophthalmol Scand 2005;83:63–66.
21. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001;21:469–477.
22. Chylack LT, Wolfe JK, Singer DM, et al. The lens opacities classification system III. Arch Ophthalmol 1993;111:831–836.
23. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125: 469–480.
24. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343–358.
25. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65–84.
26. Zhioua I, Semoun O, Lalloum F, Souied EH. Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina 2015;35:1429–1435.
27. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843–1851.
28. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122: 2044–2052.
29. Bolz M, Schmidt-Erfurth U, Deak G, et al. Diabetic Retinopathy Research Group Vienna: optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009;116:914–920.
30. Muther PS, Semkova I, Schmidt K, et al. Conditions of retinal glial and inflammatory cell activation after irradiation in a GFP-chimeric mouse model. Invest Ophthalmol Vis Sci 2010;51:4831–4839.
31. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1971–1980.
32. Qin Y, Xu G, Wang W. Dendritic abnormalities in retinal ganglion cells of three-month diabetic rats. Curr Eye Res 2006;31:967–974.
33. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol 2008;126:227–232.
34. Vujosevic S, Bini S, Midena G, et al. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res 2013;2013:491835.
35. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016;2016:2156273.
36. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006;25:397–424.
37. Moon BG, Lee JY, Yu HG, et al. Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea. J Ophthalmol 2016;2016:9810270.
38. Ferris FL III, Patz A. Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 1984;28:452–461.
39. Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012;130:1153–1161.
40. Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 2015;9:1321–1335.
41. Pelosini L, Hull CC, Boyce JF, et al. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 2011;52:2741–2748.
42. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012;119:1190–1198.
43. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX Study. Ophthalmology 2014;121:2473–2481.
44. Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2017;255: 463–473.
45. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular edema. Cochrane Database Syst Rev 2014:Cd007419. PMID:25342124.
46. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 2016;134:21–29.